Clinical trials: First Line Treatment
Pancreatic Cancer
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
Research Hypothesis: icotinib administered in combination with gemcitabine has an acceptable safety profile in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.The primary objective is to…
- Trial name
- NCT02278458
- Testing
- icotinib, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Chordoma
Afatinib in Locally Advanced and Metastatic Chordoma
In this phase 2, single arm trial patients with locally advanced or metastatic, pathologically proven, EGFR expressing chordoma will be treated with afatinib.
- Trial name
- NCT03083678
- Testing
- Afatinib
- Where
- 3 sites in Italy, Netherlands and 1 more
- Volunteers
- 43 people
- Sponsor
- Leiden University Medical Center
Pneumonic-type Adenocarcinoma (P-ADC), Lung Adenocarcinoma With Bronchiolo-alveolar Feature
Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature
Pneumonic adenocarcinoma (P-ADC) is defined as a primary lung ADC with a radiological pneumonic presentation, usually referred to histologically as ADC with a mixed-invasive and BAC predominant subtype in the 2004 WHO…
- Trial name
- NCT00198380
- Testing
- Gefitinib
- Where
- 11 sites in France
- Volunteers
- 90 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Advanced Breast Cancer, Advanced Breast Carcinoma
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
This trial studies a type of advanced breast cancer defined as hormone receptor HR-positive/HER2-negative and classified as non-luminal by gene expression profiling (PAM50).
- Conditions
- Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma
- Trial name
- PONTIAC (NCT06486883)
- Testing
- Trastuzumab deruxtecan (T-DXd, DS-8201a), CDK4/6i plus ET
- Where
- 79 sites in Austria, Belgium and 8 more
- Volunteers
- 200 people
- Sponsor
- MedSIR
Lung Cancer
APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC
The purpose of this study is to studying the addition of apatinib with chemotherapy to investigate the efficacy and safety of apatinib in combination with chemotherapy in patients with advanced NSCLC.
- Trial name
- APPEAL (NCT03164694)
- Testing
- Apatinib, Pemetrexed, Carboplatin
- Where
- China
- Sponsor
- Sun Yat-sen University
Breast Cancer Female
Adaptations to Breast Cancer and Exercise Using Telehealth (ABRACE: Telehealth)
The aim of the present study is to determine the effects of 12 weeks of multicomponent training associated with a health education program carried out remotely, compared to a health education-only program, on psychological and…
- Trial name
- NCT04641377
- Testing
- Multicomponent exercise intervention plus health education, Health Education
- Where
- 2 sites in Brazil
- Volunteers
- 36 people
- Sponsor
- Federal University of Pelotas
Renal Cancer
Dual-energy SPEctral CT to Evaluate Response to First-line Therapies in Patients With Metastatic Clear Cell REnal Cancer
To evaluate the utility of dual-energy spectral computed tomography (CT) scan in monitoring treatment in patients with metastatic clear cell carcinoma of the kidney.
- Trial name
- SPECTRE (NCT06863857)
- Where
- 2 sites in Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Non-Alcoholic Steatohepatitis
A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
The purpose of this study is to determine whether BMS-986036 is effective in the treatment of subjects with Non-alcoholic Steatohepatitis (NASH).
- Trial name
- NCT02413372
- Testing
- BMS-986036
- Where
- 17 sites in United States
- Volunteers
- 184 people
- Sponsor
- Bristol-Myers Squibb
Urothelial Carcinoma, Bladder Cancer
A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function
This study aim to compare the efficacy, safety and quality of life of vinflunine/gemcitabine and carboplatin/gemcitabine in patients with metastatic urothelial cancer and impaired renal function.
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Renal Pelvis Cancer, Ureter Cancer
- Trial name
- VINGEM (NCT02665039)
- Testing
- Vinflunine, Gemcitabine, Carboplatin
- Where
- 2 sites in Denmark, Sweden
- Volunteers
- 62 people
- Sponsor
- Dr Anders Ullén
Non-small Cell Lung Cancer, Unresectable Malignant Neoplasm
Bevacizumab in Combination With Chemotherapy in Patients With Advanced or Recurrent Non-squamous NSCLC
This observational trial is designed to assess the safety profile and tolerability of bevacizumab when combined with chemotherapy as first-line treatment of advanced or recurrent non-squamous NSCLC.
- Trial name
- NCT01963351
- Where
- Greece
- Volunteers
- 150 people
- Sponsor
- University of Athens
Metastatic Colorectal Cancer
Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab
-1498C/T VEGF polymorphism, as suggested by a recent retrospective analysis, seems to have a role in predicting the efficacy of Bevacizumab plus FOLFIRI in first-line treatment of metastatic colorectal cancer patients.
- Trial name
- PROVETTA (NCT01363739)
- Where
- Italy
- Volunteers
- 265 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Malignant Neoplasm
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog…
- Trial name
- NCT07252739
- Testing
- MK-1084, Pembrolizumab, Cetuximab
- Where
- 39 sites in United States, Chile and 11 more
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
This study is a open-label, single-center Phase 2 study to evaluate the efficacy and safety of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT.
- Trial name
- NCT05846737
- Testing
- anti-BCMA CAR-T
- Where
- China
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Extensive-stage Small Cell Lung Cancer (ES-SCLC), The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy
Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
This study is a prospective, randomized, parallel-controlled clinical trial, aiming to evaluate the efficacy and safety of nano-crystalline megestrol acetate combined with standard treatment compared to standard treatment alone…
- Trial name
- NCT06961201
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, standard treatment
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
- Trial name
- NCT01172912
- Testing
- filgrastim, pegfilgrastim, carboplatin
- Where
- Italy
- Volunteers
- 47 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
This randomised, controlled, multicentre trial is designed to assess the efficacy and safety of sequential icotinib plus chemotherapy versus single icotinib as first-line treatment in stage IIIB/IV lung adenocarcinoma patients…
- Trial name
- NCT02103257
- Testing
- Sequential Icotinib Plus Chemotherapy, Icotinib
- Where
- 31 sites in China
- Volunteers
- 192 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Steroid-refractory Acute Graft-versus-host Disease
Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease
The purpose of this trial is the comparative evaluation of overall response rate (ORR) in paediatric participants with steroid-refractory acute graft-versus-host disease (SR-aGvHD) at Visit Day 28 after treatment with MC0518 or…
- Trial name
- BALDER (NCT06075706)
- Testing
- MC0518, BAT
- Where
- 36 sites in France, Germany and 3 more
- Volunteers
- 49 people
- Sponsor
- medac GmbH
HER2 + Breast Cancer
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer
- Trial name
- NCT07294508
- Testing
- HLX87 + HLX22, HLX87 + Pertuzumab, T-Dxd + Pertuzumab
- Where
- China
- Volunteers
- 706 people
- Sponsor
- Shanghai Henlius Biotech
Malignant Neoplasm of Stomach Stage IV
POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC
The aim of this study was to compare the efficacy and safety of POF, FOLFOX, and FOLFOX plus paclitaxel(ip) as first-line treatment in AGC a phase II clinical trial.
- Trial name
- NCT02845908
- Testing
- POF, FOLFOX, FOLFOX plus PAC(ip)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fujian Cancer Hospital
Breast Cancer
A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs
The purpose of this real-world study is to understand the use of palbociclib as first treatment for Hormone receptor positive (HR+) and Human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in Canada…
- Trial name
- NCT06003114
- Testing
- Palbociclib
- Where
- Canada
- Volunteers
- 472 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.